OneSource Specialty Pharma (ONESOURCE) Stock Overview
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ONESOURCE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
OneSource Specialty Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,292.80 |
| 52 Week High | ₹2,248.00 |
| 52 Week Low | ₹1,057.00 |
| Beta | 0 |
| 1 Month Change | -9.75% |
| 3 Month Change | -18.92% |
| 1 Year Change | -4.15% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -24.40% |
Recent News & Updates
Recent updates
Some OneSource Specialty Pharma Limited (NSE:ONESOURCE) Analysts Just Made A Major Cut To Next Year's Estimates
Jan 28
A Look At The Intrinsic Value Of OneSource Specialty Pharma Limited (NSE:ONESOURCE)
Dec 15Is OneSource Specialty Pharma (NSE:ONESOURCE) A Risky Investment?
Sep 23Calculating The Fair Value Of OneSource Specialty Pharma Limited (NSE:ONESOURCE)
Aug 28Shareholder Returns
| ONESOURCE | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | -3.1% | 0.5% | -0.9% |
| 1Y | -4.1% | 2.5% | 12.2% |
Return vs Industry: ONESOURCE underperformed the Indian Life Sciences industry which returned 2.5% over the past year.
Return vs Market: ONESOURCE underperformed the Indian Market which returned 12.2% over the past year.
Price Volatility
| ONESOURCE volatility | |
|---|---|
| ONESOURCE Average Weekly Movement | 8.3% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Stable Share Price: ONESOURCE's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: ONESOURCE's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 1,412 | Neeraj Sharma | www.onesourcecdmo.com |
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products.
OneSource Specialty Pharma Limited Fundamentals Summary
| ONESOURCE fundamental statistics | |
|---|---|
| Market cap | ₹148.18b |
| Earnings (TTM) | ₹207.92m |
| Revenue (TTM) | ₹14.19b |
Is ONESOURCE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONESOURCE income statement (TTM) | |
|---|---|
| Revenue | ₹14.19b |
| Cost of Revenue | ₹4.71b |
| Gross Profit | ₹9.49b |
| Other Expenses | ₹9.28b |
| Earnings | ₹207.92m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.81 |
| Gross Margin | 66.83% |
| Net Profit Margin | 1.46% |
| Debt/Equity Ratio | 21.9% |
How did ONESOURCE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/25 03:40 |
| End of Day Share Price | 2026/02/25 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OneSource Specialty Pharma Limited is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Agarwal | DAM Capital Advisors |
| Adhidev Chattopadhyay | ICICI Securities Ltd. |
| Abdulkader Puranwala | ICICI Securities Ltd. |